Effects of a single-dose administration of Bowman-Birk inhibitor concentrate on anti-proliferation and inhabitation of metastasis in M5076 ovarian sarcoma-bearing mice

Molecular Medicine Reports

Volumn 1, Issue 6, 2008, Pages 903-907

  Sakurai, Noritaka ^a   Suzuki, Kazuyuki ^a   Sano, Yuki ^a   Saito, Teruyoshi ^a   Yoshimura, Hisashi ^a   Nishimura, Yukie ^a   Yano, Tomohiro ^b   Sadzuka, Yasuyuki ^c   Asano, Ryuji ^a  

^a NIHON UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^c IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti proliferation; Bowman Birk inhibitor; Connexin 43; Hepatic metastasis; M5076 ovarian sarcoma

Indexed keywords

BOWMAN BIRK INHIBITOR; CONNEXIN 43;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL DENSITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; INOCULATION; MALE; METASTASIS; MOUSE; NONHUMAN; OVARY; PROTEIN EXPRESSION; SARCOMA; TUMOR CELL; UPREGULATION;

MUS;

EID: 69249097445     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000048     Document Type: Article

References (35)

1. Du X, Beloussow K and Shen WC: Bowman-Brink protease inhibitor and its palmitic acid conjugate prevent 7,12-dimethylbenz [α]anthracene-induced transformation in cultured mouse mammary gland. Cancer Lett 164: 135-141, 2001. (Pubitemid 32155500)
2. Bowman DE: Differentiation of soybean antitryptic factors. Proc Soc Exp Biol Med 63: 547-550, 1946.
3. Birk Y: Purification and some properties of a highly active inhibitor of trypsin and alpha-chymotrypsin from soybeans. Biochim Biophys Acta 54: 191-197, 1961.
4. Kennedy AR: The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr 68 (Suppl 6): 1406-1412, 1998.
5. Birk Y: The Bowman-Birk protease inhibitor: trypsin- and chymotrypsin-inhibitor from soybeans. Int J Pept Protein Res 25: 113-131, 1985.
6. Losso JN: The biochemical and functional food properties of the bowman-birk inhibitor. Crit Rev Food Sci Nutr 48: 94-118, 2008.
7. Tikhonova TV, Gladysheva IP and Larionova NI: Retardation by the soybean Bowman-Birk inhibitor of elastin hydrolysis catalyzed by leukocyte proteinases. FEBS Lett 362: 225-228, 1995.
8. Kennedy AR: Chemopreventive agents; protease inhibitors. Pharmacol Ther 78: 167-209, 1998.
9. Chen YN, Huang SC, Lin-Shiau SY and Lin JK. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 26: 1296-1306, 2005.
10. Zhang YW, Nakayama K, Nakayama K and Morita I: A novel route for connexin 43 to inhibit cell proliferation: negative regulation of s-phase kinase-associated protein (skp2). Cancer Res 63: 1623-1630. 2003. (Pubitemid 36373653)
11. Suzuki K, Yano T, Saduzka Y, Sugiyama T, Seki T and Asano R: Restoration of connexin 43 by Bowman-Birk protease inhibitor in M5076-bearing mice. Oncol Rep 13: 1247-1250, 2005.
12. Malkowicz SB, McKenna WG, Vaughn DJ, et al: Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 48: 16-28, 2001. (Pubitemid 32545073)
13. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE and Meyskens FL: Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 9: 43-47, 2000. (Pubitemid 30062908)
14. Armstrong WB, Kennedy AR, Wan XS, et al: Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemo-prevention trial. Clin Cancer Res 6: 4684-4691, 2000.
15. Sugiyama T and Sadzuka Y: Combination of theanine with doxorubicin inhibit hepatic metastasis of M5076 ovarian sarcoma. Clin Cancer Res 5: 413-416, 1999. (Pubitemid 29085195)
16. Kelloff GJ, Crowell JA, Steele VE, et al: Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130: 467S-471S, 2000.
17. Stewart BW and Coates AS: Cancer prevention: a global perspective. J Clin Oncol 23: 392-403, 2005.
18. Munoz de Chavez M and Chavez A: Diet that prevents cancer: recommendations from the American Institute for Cancer Research. Int J Cancer 11: S85-S99, 1998.
19. Kennedy AR: Overview: anticarcinogenic activity of protease inhibitors. In: Protease Inhibitors as Cancer Chemopreventive Agents. Troll W and Kennedy AR (eds). Plemium Press, New York, pp9-64, 1993.
20. Kennedy AR, Kritchevsky D and Shen WC: Effects of spermine-conjugated Bowman-Birk inhibitor (spermine-BBI) on carcinogenesis and cholesterol biosynthesis in mice. Pharm Res 20: 1908-1910, 2003.
21. Yavelow J, Collins M, Birk Y, Troll W and Kennedy AR: Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc Natl Acad Sci USA 82: 5395-5399, 1985.
22. Crass RA and Morgan RGH: The effect of long-term feeding of soybean flour diets on pancreatic growth in the rat. Br J Nutr 47: 119-129, 1982.
23. Saito T, Sato H, Virgona N, et al: Negative growth control of osteosarcoma cell by Bowman-Birk protease inhibitor from soybean; involvement of connexin 43. Cancer Lett 253: 249-257, 2007. (Pubitemid 47017537)
24. Billings PC, St. Clair WH, Maki PA and Kennedy AR: Distribution of the Bowman-Birk protease inhibitor in mice following oral administration. Cancer Lett 62: 191-197, 1992.
25. Losso JN, Munene CN and Bansode RR: Inhibition of metalloproteinase-1 activity by the soybean Bowman-Birk inhibitor. Biotechnol Lett 26: 901-905, 2004. (Pubitemid 38982844)
26. Kobayashi H, Fukuda Y, Yoshida R, et al: Suppressing effects of dietary supplementation of soybean trypsin inhibitor on spontaneous, experimental and peritoneal disseminated metastasis in mouse model. Int J Cancer 112: 519-524, 2004. (Pubitemid 39390619)
27. Fujimoto E, Satoh H, Negishi E, et al: Negative growth control of renal cell carcinoma cell by connexin 32: possible involvement of Her-2. Mol Carcinog 40: 135-142, 2004. (Pubitemid 38924840)
28. Berke G, Krutovskikh V and Yamasaki H: Connexin 37 gene is not mutated in lung carcinomas 3LL and CMT. Cancer Lett 195: 67-72, 2003. (Pubitemid 36588980)
29. Hirai A, Yano T, Nishikawa K, et al: Down-regulation of connexin 32 gene expression through DNA methylation in a human renal cell carcinoma cell. Am J Nephrol 23: 172-177, 2003. (Pubitemid 36649333)
30. Salameh A and Dhein S: Pharmacology of gap junctions. New pharmacological targets for treatment of arrhythmia, seizure and cancer? Biochim Biophys Acta 1719: 36-58, 2005.
31. Kennedy AR and Wan XS: Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 50: 125-133, 2002.
32. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55-63, 2003.
33. Talmadge JE and Hart IR: Morphologic studies on a murine reticulum cell sarcoma (histiocytic sarcoma) of histiocytic origin and its metastases. Vet Pathol 20: 342-352, 1983.
34. Eugenin EA, Branes MC, Berman JW and Saez JC: TNF-α plus INF-γ induce connexin43 expression and formation of gap junctions between human monocytes/macrophages that enhance physiological responses. J Immunol 170: 1320-1328, 2003.
35. Hart IR, Talmadge JE and Fidler IJ: Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res 41: 1281-1287, 1981.